Innovation is the lifeblood of the biopharmaceutical industry and has delivered some of the most incredible life-changing innovations for safeguarding and improving health. Policy and legal frameworks must therefore continue to incentivise and create environments that drive innovation for long-term wellbeing and economic growth, as well as providing solid platforms for response to new and emerging health threats.
INTERPAT
NGO · Switzerland
Counts here are a floor, never a total: they cover the 583 consultation files tracked so far (42,224 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.
Track INTERPAT in PolicySpeak: request access →
Work at INTERPAT? so we know who speaks for it.
Their record over time
INTERPAT filed 2 positions between 5 Apr 2022 and 29 Apr 2022, across 2 of the 583 legislative files tracked here, attaching a full position paper 2 times.
What they argued
INTERPAT is a global trade association of Chief intellectual property (IP) Counsels from the biopharmaceutical industry that seeks to share knowledge, experience and expertise in creating and nurturing sustainable innovation ecosystems in life sciences.
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Put INTERPAT next to another organization. Same files, same register facts, side by side. Compare →
Turns up on the same files
Organizations that also filed on at least two of the same consultations. A shared interest in the same dossiers — not evidence of coordination, and we do not suggest any.
Showing 5 of 19.
Is this your organization?
Everything on this page comes from INTERPAT’s own submissions to the European Commission — we have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.